Biocon Limited operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biocon Limited with three other
pharmaceutical manufacturers in Asia:
Green Cross Corporation
of South Korea
sales of 1.37 trillion Korean Won [US$1.16 billion]
Panacea Biotec Ltd
(4.51 billion Indian Rupees [US$63.16 million]
of which 80%
was Formulation), and
Pharma Foods International Co.Ltd
based in Japan
(10.53 billion Japanese Yen [US$95.64 million]
of which 81%
was Functional product(Online business)).
Biocon Limited reported sales of 55.14 billion Indian Rupees (US$773.12 million)
March of 2019.
increase of 33.7%
versus 2018, when the company's sales were 41.23 billion Indian Rupees.
Sales at Biocon Limited have increased during each of the previous five years
(and since 2014, sales have increased a total of 92%).
Sales of Biologics saw an increase
that was more than double the company's growth rate: sales were up
96.9% in 2019, from
7.70 billion Indian Rupees to 15.17 billion Indian Rupees.